Bicyclol combined with ganciclovir for treatment of infantile cytomegalovirus hepatitis.
- Author:
Yan-Hong LIU
1
;
Mei-Yun JIA
;
Gui-Juan LIANG
;
Hai-Shan GUAN
;
An-Ping YAN
Author Information
- Publication Type:Journal Article
- MeSH: Alanine Transaminase; metabolism; Alkaline Phosphatase; metabolism; Antiviral Agents; therapeutic use; Bilirubin; blood; Biphenyl Compounds; therapeutic use; Cytomegalovirus; Cytomegalovirus Infections; drug therapy; Drug Therapy, Combination; Ganciclovir; therapeutic use; Hepatitis; drug therapy; virology; Humans; Infant; Liver Function Tests
- From: Journal of Southern Medical University 2015;35(10):1505-1507
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the therapeutic effects of bicyclol combined with ganciclocir on infantile cytomegalovirus hepatitis.
METHODSSeventy infants with cytomegalovirus hepatitis were randomized into treatment group (n=35) and control group (n=35) for a 2-week-long treatment with ganciclocir (5 mg/kg) with and without oral bicyclol (3 mg/kg, twice daily), respectively.
RESULTSIn both groups, significant changes occurred in the levels of alanine aminotransferase, alkaline phosphatase, serum total bilirubin, serum total bile acid, and glutamyl transpeptidase after the 2-week treatment (P<0.01); these parameters differed significantly between the two groups after the treatment (P<0.01). Compared with those in the control group, the infants in the treatment group showed significantly better responses to the treatment (P<0.05) with a significantly higher rate of serum anti CMV IgM negativity (P<0.05).
CONCLUSIONSBicyclol combined with ganciclocir can reduce glutamic pyruvic transaminase, alkaline phosphatase and serum total bilirubin, and decrease bile acid levels to lessen liver cell damage and promote the recovery of liver cells.
